Promising combo tackles tough prostate cancer
NCT ID NCT02023463
First seen Jan 05, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study tests a three-part treatment for men with intermediate or high-risk prostate cancer: a drug called enzalutamide, radiation therapy, and hormone therapy. The goal is to see how safe the combination is and how well it controls the cancer. About 25 men will take part, and researchers will monitor side effects and changes in PSA levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.